Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Mice Protected by Vaccine Based on Genetically Weakened Pneumonia Bacteria

By LabMedica International staff writers
Posted on 10 Mar 2011
By introducing a mutation into the bacterial gene that codes for the virulence factor pneumolysin, a research team has created a potential new vaccine to protect against pneumococcal pneumonia caused by Streptococcus pneumoniae.

Pneumolysin is a 53-kDa pore-forming toxin composed of 471 amino acids. More...
It has a range of biological activities including the ability to lyse and interfere with the function of cells and soluble molecules of the immune system. Secreted pneumolysin aids the bacteria during colonization, by facilitating adherence to the host, during invasion by damaging host cells, and during infection by interfering with the host immune response.

Investigators at the Albert Einstein College of Medicine (New York, NY, USA) used a previously described method of controlling gene expression with computer-based gene design and de novo DNA synthesis to attenuate the virulence of Streptococcus pneumoniae. They produced two weakened S. pneumoniae serotype 3 (SP3) strains in which the pneumolysin gene (ply) was recoded with underrepresented codon pairs while retaining its amino acid sequence.

Results of studies conducted with these modified strains were published in the February 21, 2011, online edition of the Journal of Infectious Diseases. They revealed that expression of ply and production of pneumolysin by the recoded SP3 strains were decreased, and the recoded SP3 strains were less virulent in mice than the wild-type SP3 strain or a delta-ply SP3 strain. The least virulent recoded strain induced a markedly reduced inflammatory response in the lungs compared with the wild type or delta-ply strain. Despite the reduced inflammatory response engendered by the mutated bacteria, an immune response was generated that protected the mice from subsequent challenge with the wild-type strain of S. pneumoniae.

"Our idea was to design a live vaccine that would stimulate the immune system sufficiently to ward off disease but would not lead to the severely damaging inflammatory response that this strain can cause,” said first author Dr. J. Robert Coleman, a postdoctoral fellow in microbiology and immunology at the Albert Einstein College of Medicine. "The novelty of this approach lies in the fact that the gene's expression would be reduced, but not eliminated. Previous approaches to genetic regulation of virulence relied on knocking out genes, which eliminates their expression completely.”

Related Links:

Albert Einstein College of Medicine





New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.